In the media February 28, 2023
BrainsWay’s Chief Medical Officer, Dr. Aron Tendler details six things to understand about Deep...
News February 23, 2023
BURLINGTON, Mass. and JERUSALEM, Feb. 23, 2023 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...
Events November 14 - November 17, 2024
BrainsWay is attending the World Congress of Psychiatry Conference from November 14 to November 17, 2024,...
News February 13, 2023
BURLINGTON, Mass. and JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...
News February 13, 2023
David Zacut, M.D., Relinquishing Chairman Role Held Since Company’s Inception, to Now Serve as Board...
In the media February 9, 2023
BrainsWay’s recent research on the H1 and H7 Coils (for the treatment of depression and OCD, respectively),...
In the media February 6, 2023
Article covering a recent study published in The Annals of Clinical Psychiatry, which showed that rTMS...
In the media February 7, 2023
Summary of the H1 and H7 Coil (for the treatment of depression and OCD, respectively) clinical data and...
In the media February 2, 2023
Dr. Hanlon, VP of Clinical Affairs for BrainsWay, details her medical journey and inspiration found in...
In the media January 31, 2023
Press release detailing BrainsWay’s FDA clearance for the treatment of depression using the H7...
In the media January 31, 2023
Dr. Colleen Hanlon, VP of Medical Affairs shares her expertise and experience in the field of addiction,...
In the media January 28, 2023
Todu Guam Foundation offers the first TMS device for the treatment of depression in Guam. Foundation...
In the media January 29, 2023
Todu Guam Foundation offers the first TMS device for the treatment of depression in Guam. BrainsWay representative...
News January 31, 2023
Study Results Outline a Potential Path to More Personalized Medicine in Noninvasive Brain Stimulation BURLINGTON,...
News January 11, 2023
BURLINGTON, MA and JERUSALEM, Israel, Jan. 11, 2023 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ &...
News January 10, 2023
BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2023 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...
